Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MGD013 ± zanubrutinib in advanced liver cancer
CTR20200549Phase 2Terminated
- Sponsor
- Zai Lab
- Start
- Apr 2020
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of tebotelimab, zanubrutinib in hepatocellular carcinoma (HCC), intrahepatic cholangiocarcinoma (ICC), sponsored by Zai Lab. Started Apr 2020; status: terminated.
02
Drugs
tebotelimabzanubrutinib
03
Conditions
hepatocellular carcinoma (HCC)intrahepatic cholangiocarcinoma (ICC)
Beyond the preview
Go deeper on CTR20200549.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20200549.